devin_effinger Profile Banner
Devin Effinger, PhD Profile
Devin Effinger, PhD

@devin_effinger

Followers
3K
Following
4K
Media
137
Statuses
611

Postdoc at @cuanschutz researching #psychedelics | lived experience of TBI & SUD #recovery | Board member, @winter_brain

Boulder, CO
Joined December 2020
Don't wanna be here? Send us removal request.
@devin_effinger
Devin Effinger, PhD
29 days
My TEDx talk is live! I share my path from TBI to heroin addiction to neuroscientist, along with simple strategies for resilience and top-down control. I’d truly appreciate you sharing it. https://t.co/WqDD5HjAfr
1
4
12
@dpn_journal
NPP-Digital Psychiatry and Neuroscience (DPN)
1 month
Researchers with lived experience of mental illness or SUDs bring vital expertise & insight to our field, yet remain underrepresented and face barriers to participation and leadership. This Perspective from @UmaRChatterjee, @SchumerMaya, @devin_effinger, @viscidula, @noelvest,
nature.com
NPP—Digital Psychiatry and Neuroscience - Breaking barriers: centering researchers with lived experience in psychiatric neuroscience
0
15
24
@MassalyNiko
Niko Massaly
2 months
🚨 Please RT! We’re recruiting a motivated postdoc to dissect the neurocircuits of affective pain. Expertise in behavioral models of pain/SUDs, stereotaxy, microscopy, opto/chemogenetics, or fiber photometry encouraged. Apply 👉 https://t.co/3MvLGA75nH #Neuroscience #Postdoc
Tweet card summary image
recruit.apo.ucla.edu
University of California, Los Angeles is hiring. Apply now!
1
36
44
@devin_effinger
Devin Effinger, PhD
3 months
If anyone is looking (or know of someone) for a roommate and has a spot at the Atlantis for @ACNPorg , please let me know!
0
5
3
@_TheTransmitter
The Transmitter
3 months
Devin Effinger @devin_effinger and @MelissaHerman4 argue that, though many human psychedelic clinical trials are underway, preclinical studies remain our best bet to answer fundamental questions about the neurobiology of psychedelics. https://t.co/4HBcJSMtnK
Tweet card summary image
thetransmitter.org
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering…
0
12
25
@devin_effinger
Devin Effinger, PhD
3 months
What an honor! Humbled and grateful. It was a beautiful disaster and a perfect metaphor for my recovery ending with a standing ovation. Thank you so much to the organizers and stay tuned for the link! @TEDxBoulder
1
5
16
@devin_effinger
Devin Effinger, PhD
4 months
Takeaway: In mice, 8 weeks of low-dose LSD produced no evidence of heart damage. But human studies are still essential — especially in people with cardiovascular risk factors.
0
0
2
@devin_effinger
Devin Effinger, PhD
4 months
Pharmacokinetic modeling gave us a potential explanation: 👉 Fenfluramine is still present in blood at 24h, leading to sustained and chronic 5-HT2B activation. 👉 Low doses of LSD and psilocin are both off the receptor within 8-10h.
2
0
2
@devin_effinger
Devin Effinger, PhD
4 months
We tested this by giving mice low-dose LSD (microdoses) 5 days per week for 8 weeks and tracked heart structure and function with echocardiography. 🫀 Serotonin & fenfluramine (positive controls) led to ventricular or valvular remodeling. 🫀 LSD had no effects.
1
0
1
@devin_effinger
Devin Effinger, PhD
4 months
🚨 New paper 🚨 For years, there has been concern that psychedelics might pose cardiovascular risks due to their agonist activity at the 5-HT2B receptor — the same target linked to drug-induced heart disease. https://t.co/PsDxP24wKT
Tweet card summary image
pubs.acs.org
Microdosing, the prolonged ingestion of psychedelics at subhallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT2B...
4
12
45
@SchumerMaya
Maya Schumer, PhD!
4 months
@ACNPorg brought @UmaRChatterjee @devin_effinger & me together last year: After finding each other on X-as we are all public/open about our lived experience -we met and discussed the ideas for this Study Group! Looking forward to doing this work together@ #ACNP2026🧠❤️💥‼️
@UmaRChatterjee
Uma R. Chatterjee, M.S., MHPS
4 months
THRILLED to share @ACNPorg news x2! 1) Our study group—“Centering Lived Experience in Psychiatric Neuroscience Research: Challenges, Opportunities, & Calls to Action” @EricJNestler @BStaglin @SchumerMaya @devin_effinger @viscidula @noelvest @MichaelECahill1=ACCEPTED! 🤩#ACNP2026
1
11
22
@UmaRChatterjee
Uma R. Chatterjee, M.S., MHPS
4 months
THRILLED to share @ACNPorg news x2! 1) Our study group—“Centering Lived Experience in Psychiatric Neuroscience Research: Challenges, Opportunities, & Calls to Action” @EricJNestler @BStaglin @SchumerMaya @devin_effinger @viscidula @noelvest @MichaelECahill1=ACCEPTED! 🤩#ACNP2026
2
7
24
@zenbrainest
BryanRoth
5 months
My recent email to @NIHDirector_Jay @RobertKennedyJr Please RT!
1
23
44
@devin_effinger
Devin Effinger, PhD
5 months
It’s wild how much change is possible in this life. From relearning to talk post-TBI, to full blown heroin addiction, to a life beyond anything I could have imagined. Im very fortunate to not only be alive, but to have been selected to speak at 2025 TEDxBoulder!
5
9
59
@ArgelAV
@argelaguilarvalles.bsky.social
6 months
🚨 New preprint alert! Intranasal esketamine helps with treatment-resistant depression—but do sex differences shape who responds best, and how? We analyzed 5 RCTs and found striking sex-specific symptom patterns. 👉 https://t.co/lr5yWi6qlm #Depression #Esketamine
Tweet card summary image
medrxiv.org
Background Racemic ketamine and its enantiomer, esketamine, have emerged as fast-acting antidepressant options for individuals with treatment-resistant depression (TRD). Yet, despite growing clinical...
2
6
11
@devin_effinger
Devin Effinger, PhD
5 months
The inaugural #GRCPsychedelics was a success! I am honored to have been one of a few chosen to receive a travel award and be able to share the stage with the leaders in the field. Very grateful to the organizers. 🙏 @kwanalexc @VVyazovskiy @MelissaHerman4 @ViditaVaidya
0
5
24
@TheBorisLab
Boris D Heifets
5 months
Save the date for Psychedelics GRC ***2029***!!
@kwanalexc
Alex Kwan 關進晞
5 months
We worked so well as a team for the #GRCPsychedelics @VVyazovskiy @MelissaHerman4 @ViditaVaidya and congrats to @TheBorisLab and @MikaelPalner, who will be the future vice-chairs!
3
10
59
@FredBarrettPhD
Frederick Barrett
7 months
I had deactivated my account out of a sense of mental preservation, and was planning to log back in every 29 days to preserve my history and connections, but I apparently failed at that task. I'm now slowly rebuilding my twitter network.
1
2
13
@ShihYYI
Ian Shih
8 months
Come meet @camri_unc members during @ISMRM! On Saturday (May 10) at the @bruker event and Monday (May 12) at 14:01 in the fMRI power pitch session, @TzuHaoHarryChao will talk about his work mapping inter-brain functional connectivity in socially interacting mice using SORDINO.
1
6
21
@devin_effinger
Devin Effinger, PhD
8 months
It’s a common misconception that, for the person with a SUD, the substances are the problem. In my experience, the real problem was much deeper. Until I addressed the underlying causes/conditions, longterm sobriety was unattainable. Link in bio. #sober #sobriety #RecoveryPosse
2
5
24